Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors

• Main Authors: Xiaoyan KANG, Nan ZHU, Xia SONG
• Format: Article
• Language: zho
• Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2016-10-01
• Series: Chinese Journal of Lung Cancer
• Subjects: Lung neoplasms; BRAF; Inhibitors
• Online Access: http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.13

In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors targeted at BRAF gene have obviously clinical efficacy to specific advantages populations with little side-effect, and be well tolerated. It is discovered recently that drug resistance also exists in BRAF inhibitors like other targeted drugs, the mechanism of drug resistance is being studied. In this paper, a review were performed in the mechanism, clinical application, adverse reactions and the drug resistance of BRAF inhibitors.